once monthly glp 1 Injections of an ultra-long-acting investigational GLP-1 agonist led to significant weight loss in people with overweight or obesity, with reductions continuing after a switch to once-monthly dosing, according to the ongoing VESPER Pfizer's Metsera GLP-1 hits mark

While Wegovy and Zepbound added non-weight-loss indications, this second payer, instead, moved to outright rejecting claims between 70% and 80% of the time

A fair look at Ro: program overview, medication approach, pricing, and the genetic variable the brand does not address

On the flipside, there are challenges: for example, concerns about cost to healthcare systems and equity of access for patients with the greatest unmet needs, or the possible impact on Medtech currently used by patients suffering from obesity related conditions for example knee replacements for overweight patients with eroded joints or CPAP machines for sleep apnoea, a complication of obesity

Why Muscle Loss Is the Real Challenge for GLP-1 Users GLP-1 medications work by reducing appetite and slowing digestion, which leads to a significant calorie deficit over time